Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials
- 1 December 2004
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (23) , 4810-4815
- https://doi.org/10.1200/jco.2004.03.121
Abstract
Purpose: To describe the prevalence, clinical characteristics, and pattern of use of complementary and alternative medicine (CAM) in patients enrolled onto phase I trials. Patients and Methods: Questionnaires were administered to 108 patients with advanced malignancies enrolled onto phase I chemotherapy trials at the Mayo Clinic Comprehensive Cancer Center (Rochester, MN). CAM was classified into two modalities, pharmacologic and nonpharmacologic. Clinical and demographic data, including age, sex, and prior cancer treatment, were subsequently obtained from patient charts and examined for any correlation with CAM use, using χ2 analysis. Results: One hundred two survey forms were returned. Among respondents, 88.2% (90 of 102) had used at least one CAM modality; 93.3% (84 of 90) and 53.3% (48 of 90) had used pharmacologic and nonpharmacologic CAM, respectively; and 46.7% (42 of 90) used both modalities. Vitamin and mineral preparations constituted 89.3% (75 of 84) of all pharmacologic CAM used. Intake was highest for vitamins E (48.8% [41 of 84]) and C (38.1% [32 of 84]), and 71.4% (60 of 84) of respondents took nonvitamin/mineral agents. Green tea (29.8% [25 of 84]), echinacea (13.1% [11 of 84]), and essiac (9.5% [8 of 84]) were the most popular. Prayer and spiritual practices were the most commonly used nonpharmacologic CAM, accounting for 52.1% (25 of 48). Chiropractors, the most frequently visited nontraditional medicine practitioners, were consulted by only 10% (9 of 90) of those who practiced CAM. Both CAM modalities were used more frequently by women (53.5% [23 of 43]) than men (40.4% [19 of 47]). Conclusion: CAM use is common among patients in phase I trials and should be ascertained by investigators, because some of the agents used may interact with investigational agents and affect adverse effects and/or efficacy.Keywords
This publication has 31 references indexed in Scilit:
- Novel pharmacological agents in clinical development for solid tumoursExpert Opinion on Investigational Drugs, 2001
- An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tincturesPhytomedicine, 2000
- Use of Alternative Medicine by Women with Early-Stage Breast CancerNew England Journal of Medicine, 1999
- Polyphenols as cancer chemopreventive agentsJournal of Cellular Biochemistry, 1995
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994
- The prevalence of questionable methods of cancer treatment in the United StatesCA: A Cancer Journal for Clinicians, 1992
- Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growthAnti-Cancer Drugs, 1990
- Immunomodulation with Viscum Album and Echinacea Purpurea ExtractsOncology Research and Treatment, 1987
- Distribution Free Tests of Independence Based on the Sample Distribution FunctionThe Annals of Mathematical Statistics, 1961
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIALBiometrika, 1934